Darlene M Deptula-hicks - Net Worth and Insider Trading
Darlene M Deptula-hicks Net Worth
The estimated net worth of Darlene M Deptula-hicks is at least $55,936 dollars as of 2024-12-28. Darlene M Deptula-hicks is the Executive VP of Finance, CFO of icad Inc and owns about 28,237 shares of icad Inc (ICAD) stock worth over $55,062. Darlene M Deptula-hicks is the SVP, CFO of Pieris Pharmaceuticals Inc and owns about 63 shares of Pieris Pharmaceuticals Inc (PIRS) stock worth over $857. Darlene M Deptula-hicks is also the SVP & CFO of T2 Biosystems Inc and owns about 40 shares of T2 Biosystems Inc (TTOO) stock worth over $17. Details can be seen in Darlene M Deptula-hicks's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Darlene M Deptula-hicks has not made any transactions after 2017-06-06 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Darlene M Deptula-hicks
Darlene M Deptula-hicks Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Darlene M Deptula-hicks owns 6 companies in total, including Xenetic Biosciences Inc (XBIO) , T2 Biosystems Inc (TTOO) , and Pieris Pharmaceuticals Inc (PIRS) among others .
Click here to see the complete history of Darlene M Deptula-hicks’s form 4 insider trades.
Insider Ownership Summary of Darlene M Deptula-hicks
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| XBIO | Xenetic Biosciences Inc | 2016-11-01 | director |
| TTOO | T2 Biosystems Inc | 2017-06-06 | Chief Financial Officer |
| PIRS | Pieris Pharmaceuticals Inc | 2016-06-13 | Sr. Vice President and CFO |
 | | 2010-03-11 | Executive VP of Finance & CFO |
| | 2006-03-15 | director |
| | 2023-03-08 | See Remarks |
Darlene M Deptula-hicks Latest Holdings Summary
Darlene M Deptula-hicks currently owns a total of 3 stocks. Among these stocks, Darlene M Deptula-hicks owns 28,237 shares of icad Inc (ICAD) as of March 11, 2010, with a value of $55,062 and a weighting of 98.44%. Darlene M Deptula-hicks owns 63 shares of Pieris Pharmaceuticals Inc (PIRS) as of June 13, 2016, with a value of $857 and a weighting of 1.53%. Darlene M Deptula-hicks also owns 40 shares of T2 Biosystems Inc (TTOO) as of June 6, 2017, with a value of $17 and a weighting of 0.03%.
Latest Holdings of Darlene M Deptula-hicks
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| ICAD | icad Inc | 2010-03-11 | 28,237 | 1.95 | 55,062 |
| PIRS | Pieris Pharmaceuticals Inc | 2016-06-13 | 63 | 13.60 | 857 |
| TTOO | T2 Biosystems Inc | 2017-06-06 | 40 | 0.43 | 17 |
Holding Weightings of Darlene M Deptula-hicks
Darlene M Deptula-hicks Form 4 Trading Tracker
According to the SEC Form 4 filings, Darlene M Deptula-hicks has made a total of 0 transactions in icad Inc (ICAD) over the past 5 years. The most-recent trade in icad Inc is the sale of 5,000 shares on March 11, 2010, which brought Darlene M Deptula-hicks around $35,000.
According to the SEC Form 4 filings, Darlene M Deptula-hicks has made a total of 0 transactions in Pieris Pharmaceuticals Inc (PIRS) over the past 5 years. The most-recent trade in Pieris Pharmaceuticals Inc is the acquisition of 63 shares on June 13, 2016, which cost Darlene M Deptula-hicks around $8,300.
According to the SEC Form 4 filings, Darlene M Deptula-hicks has made a total of 0 transactions in T2 Biosystems Inc (TTOO) over the past 5 years. The most-recent trade in T2 Biosystems Inc is the acquisition of 40 shares on June 6, 2017, which cost Darlene M Deptula-hicks around $14,320.
Insider Trading History of Darlene M Deptula-hicks
- 1
Darlene M Deptula-hicks Trading Performance
GuruFocus tracks the stock performance after each of Darlene M Deptula-hicks's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Darlene M Deptula-hicks is 10.62%. GuruFocus also compares Darlene M Deptula-hicks's trading performance to market benchmark return within the same time period. The performance of stocks bought by Darlene M Deptula-hicks within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Darlene M Deptula-hicks's insider trading performs compared to the benchmark.
Performance of Darlene M Deptula-hicks
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | -5.55 | | | | | |
| Relative Return to S&P 500(%) | -6.91 | | | | | |
Darlene M Deptula-hicks Ownership Network
Darlene M Deptula-hicks Owned Company Details
What does Xenetic Biosciences Inc do?
Who are the key executives at Xenetic Biosciences Inc?
Darlene M Deptula-hicks is the director of Xenetic Biosciences Inc. Other key executives at Xenetic Biosciences Inc include Chief Financial Officer James F Parslow , Chief Scientific Officer Curtis Lockshin , and 10 percent owner Pharmsynthez Pjsc .
Xenetic Biosciences Inc (XBIO) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Xenetic Biosciences Inc (XBIO) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Xenetic Biosciences Inc (XBIO) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Xenetic Biosciences Inc (XBIO)'s detailed insider trading history can be found in Insider Trading Tracker table.
Xenetic Biosciences Inc Insider Transactions
Darlene M Deptula-hicks Mailing Address
Above is the net worth, insider trading, and ownership report for Darlene M Deptula-hicks. You might contact Darlene M Deptula-hicks via mailing address: C/o Icad, Inc., 98 Spit Brook Road, Suite 100, Nashua Nh 03062.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
